Skip to main content

Reference

Peptide Regulatory Status Tracker

The status of 59 peptides under three rule sets: US FDA drug approval, FDA's section 503A compounding categories, and the 2026 WADA Prohibited List. As of Nov 10, 2026, 10 are in FDA-approved drugs, 21 are prohibited by name or class on the WADA List, and six (BPC-157, Epitalon, KPV, MOTS-c, Semax, TB-500) are covered by a draft HHS compounding policy without being FDA-approved.

Checked against each source on Nov 10, 2026

What changed in 2026

  1. Apr 22, 2026

    FDA removed a group of peptides from 503A Category 2 after their nominations were withdrawn, including BPC-157, TB-500, CJC-1295, KPV, MOTS-c, Semax, Selank and Epitalon. GHK-Cu was also taken out of Category 1. [3][6]

  2. May 14, 2026

    FDA's updated category list places GHK-Cu, for routes other than injection, back in Category 1. Injectable GHK-Cu remains a withdrawn nomination. [2]

  3. Jul 24, 2026

    FDA's Pharmacy Compounding Advisory Committee voted to recommend adding BPC-157, TB-500, KPV, MOTS-c, Epitalon and Semax to the 503A bulks list, and voted against emideltide (DSIP). The votes are advisory. [5]

  4. Oct 30, 2026

    HHS published a draft enforcement discretion policy covering 503A compounding with those six peptides while FDA decides, through rulemaking, whether to add them to the 503A bulks list. [4]

Status by compound

Select a compound to open its guide. The legend below the table explains each status.

FDA approval, 503A compounding status and WADA status by compound, checked Nov 10, 2026
CompoundFDA approval (US)503A compounding (US)WADA 2026
ACE-031Not FDA-approvedNot in a categoryProhibited · S4.3

Named as a decoy activin receptor.

AdipotideNot FDA-approvedNot in a categoryNot named · S0 rule
AlbiglutideApproved, discontinued

Tanzeum, approved 2014.

Not applicableNot named · S0 rule

Discontinued worldwide; S0 covers discontinued drugs.

AmycretinNot FDA-approvedNot in a categoryNot named · S0 rule
AOD-9604Not FDA-approvedNomination withdrawn

Removed from Category 2 after the nomination was withdrawn.

Prohibited · S2.2.3

Named as a growth hormone fragment.

ArgirelineNot FDA-approved

Cosmetic ingredient.

Not in a categoryNot on the List
BPC-157Not FDA-approvedHHS enforcement discretion

Draft HHS policy, Oct 30, 2026; PCAC recommended adding it to the 503A bulks list in July 2026.

Prohibited · S0

Named in S0.

BremelanotideFDA-approved

Vyleesi, 2019.

Not applicableNot on the List
CagrilintideNot FDA-approvedNot in a categoryNot named · S0 rule
CerebrolysinNot FDA-approved

Approved in some other countries.

Not in a categoryNot on the List
CJC-1295Not FDA-approvedNomination withdrawn

Removed from Category 2 after the nomination was withdrawn.

Prohibited · S2.2.4

Named as a GHRH analogue.

DapiglutideNot FDA-approvedNot in a categoryNot named · S0 rule
DihexaNot FDA-approvedNomination withdrawn

Removed from Category 2 after the nomination was withdrawn.

Not named · S0 rule
DSIP (emideltide)Not FDA-approvedNomination withdrawn

Removed from Category 2 after the nomination was withdrawn; PCAC voted against adding it to the 503A bulks list in July 2026.

Not named · S0 rule
DulaglutideFDA-approved

Trulicity, 2014.

Not applicableNot on the List
EcnoglutideNot FDA-approvedNot in a categoryNot named · S0 rule
ElamipretideFDA-approved

Forzinity, 2025 (accelerated approval).

Not applicableNot on the List
EpitalonNot FDA-approvedHHS enforcement discretion

Draft HHS policy, Oct 30, 2026; PCAC recommended adding it to the 503A bulks list in July 2026.

Not named · S0 rule
ExenatideFDA-approved

Byetta, 2005; Bydureon.

Not applicableNot on the List
Follistatin-344Not FDA-approvedNot in a categoryProhibited · S4.3

Follistatin is named as a myostatin-binding protein.

GHK-CuNot FDA-approved

Cosmetic ingredient.

Category 1

Category 1 for routes other than injection (May 14, 2026). The injectable nomination was withdrawn from Category 2.

Not on the List
GHRP-2Not FDA-approvedCategory 3

503A Category 3; 503B Category 2 for injectable and nasal routes.

Prohibited · S2.2.4

Named as a GH-releasing peptide.

GHRP-6Not FDA-approvedCategory 3

503A Category 3; 503B Category 2.

Prohibited · S2.2.4

Named as a GH-releasing peptide.

GlutathioneNot FDA-approved

Not approved as a stand-alone drug; an ingredient of BSS Plus irrigation solution.

Category 1Not on the List
GonadorelinApproved, discontinued

Factrel, approved 1982.

Not applicableProhibited · S2.2.1

Named; prohibited in males.

HexarelinNot FDA-approvedNot in a categoryProhibited · S2.2.4

Named as examorelin (hexarelin).

HumaninNot FDA-approvedNot in a categoryNot named · S0 rule
IGF-1 DESNot FDA-approvedNot in a categoryProhibited · S2.3

IGF-1 analogues are named.

IGF-1 LR3Not FDA-approvedNot in a categoryProhibited · S2.3

IGF-1 analogues are named.

IpamorelinNot FDA-approvedNomination withdrawn

503A nomination withdrawn from Category 2; 503B Category 2.

Prohibited · S2.2.4

Named as a growth hormone secretagogue.

Kisspeptin-10Not FDA-approvedCategory 2Prohibited · S2.2.1

Kisspeptin and its analogues are named; prohibited in males.

KPVNot FDA-approvedHHS enforcement discretion

Draft HHS policy, Oct 30, 2026; PCAC recommended adding it to the 503A bulks list in July 2026.

Not named · S0 rule
LiraglutideFDA-approved

Victoza, 2010; Saxenda, 2014.

Not applicableNot on the List
LixisenatideFDA-approved

Adlyxin, 2016; also in Soliqua 100/33.

Not applicableNot on the List
LL-37Not FDA-approvedNomination withdrawn

Removed from Category 2 after the nomination was withdrawn.

Not named · S0 rule
MatrixylNot FDA-approved

Cosmetic ingredient.

Not in a categoryNot on the List
MazdutideNot FDA-approved

Approved in China.

Not in a categoryNot on the List
Melanotan IINot FDA-approvedNomination withdrawn

Removed from Category 2 after the nomination was withdrawn.

Not named · S0 rule
MGFNot FDA-approvedCategory 3Prohibited · S2.3

Mechano growth factors are named.

Mod GRF 1-29Not FDA-approvedNot in a categoryProhibited · S2.2.4

Within GHRH and its analogues.

MOTS-cNot FDA-approvedHHS enforcement discretion

Draft HHS policy, Oct 30, 2026; PCAC recommended adding it to the 503A bulks list in July 2026.

Prohibited · S4.4.1

Named as an AMPK activator.

NAD+Not FDA-approvedCategory 1Not on the List
OxytocinFDA-approved

Pitocin and generic oxytocin injection.

Not applicableNot on the List
P21Not FDA-approvedNot in a categoryNot named · S0 rule
PEG-MGFNot FDA-approvedNomination withdrawn

Removed from Category 2 after the nomination was withdrawn.

Prohibited · S2.3

Mechano growth factors are named.

PemvidutideNot FDA-approvedNot in a categoryNot named · S0 rule
PNC-27Not FDA-approvedNot in a categoryNot named · S0 rule
RetatrutideNot FDA-approvedNot in a categoryNot named · S0 rule
SelankNot FDA-approved

Approved in Russia.

Nomination withdrawn

Removed from Category 2 after the nomination was withdrawn.

Not on the List
SemaglutideFDA-approved

Ozempic, 2017; Rybelsus, 2019; Wegovy, 2021.

Not applicableNot on the List
SemaxNot FDA-approved

Approved in Russia.

HHS enforcement discretion

Draft HHS policy, Oct 30, 2026; PCAC recommended adding it to the 503A bulks list in July 2026.

Not on the List
SermorelinApproved, discontinued

Geref, approved 1990.

Not applicableProhibited · S2.2.4

Named as a GHRH analogue.

SurvodutideNot FDA-approvedNot in a categoryNot named · S0 rule
TB-500Not FDA-approvedHHS enforcement discretion

Draft HHS policy, Oct 30, 2026; PCAC recommended adding it to the 503A bulks list in July 2026.

Prohibited · S2.3

Named as a thymosin-β4 derivative.

TesamorelinFDA-approved

Egrifta, 2010.

Not applicableProhibited · S2.2.4

Named as a GHRH analogue.

Thymalfasin (thymosin α1)Not FDA-approved

Approved in other countries.

Nomination withdrawn

Removed from Category 2 after the nomination was withdrawn.

Not on the List
Thymosin beta-4Not FDA-approvedNot in a categoryProhibited · S2.3

Thymosin-β4 is named.

TirzepatideFDA-approved

Mounjaro, 2022; Zepbound, 2023.

Not applicableNot on the List
VIPNot FDA-approvedCategory 1Not on the List

What each status means

FDA approval

FDA-approved
Drugs@FDA lists an approved application for a product containing the compound.
Approved, discontinued
FDA approved a product, but every product containing the compound has since been discontinued in the US.
Not FDA-approved
Drugs@FDA lists no approved product containing the compound.

503A compounding

HHS enforcement discretion
Covered by the October 30, 2026 draft HHS policy: HHS does not intend to take enforcement action against licensed pharmacies and physicians compounding it under section 503A while FDA rulemaking proceeds.
Category 1
Nominated and under evaluation; FDA has not identified significant safety risks.
Category 2
FDA has identified significant safety risks.
Category 3
Nominated without adequate supporting information.
Nomination withdrawn
Formerly in Category 2; the nomination was withdrawn, so the substance is no longer in any category.
Not applicable
An FDA-approved drug. The nomination categories cover bulk substances that are not components of approved drugs.
Not in a category
Not in any of FDA's 503A nomination categories.

WADA Prohibited List

Prohibited
Named on the List, or within a class the List names, at the section shown.
Not named · S0 rule
Not named, but WADA's S0 class prohibits any substance with no current approval by a health authority anywhere for human therapeutic use, including drugs in development.
Not on the List
Not named on the List. S0 does not reach a substance approved as a medicine somewhere; for cosmetic and supplement ingredients, an anti-doping organization can confirm status.

How to read this table

The three columns answer different questions. FDA approval says whether a finished drug product containing the compound has been approved. The 503A column covers whether state-licensed pharmacies may use the compound as a bulk ingredient in compounding, which is a separate process from approval. The WADA column applies only to athletes subject to the World Anti-Doping Code.

A status in one column says nothing about the others. A peptide can be covered by the HHS compounding policy, not FDA-approved, and prohibited by WADA at the same time, as BPC-157 is.

Frequently asked questions

Is BPC-157 FDA-approved?

No. No product containing BPC-157 is FDA-approved. FDA removed it from 503A Category 2 in April 2026, and a draft HHS policy published on October 30, 2026 says HHS does not intend to take enforcement action against licensed pharmacies and physicians compounding it under section 503A while FDA rulemaking proceeds. WADA names it as prohibited under S0.

Which peptides does the October 2026 HHS compounding policy cover?

Six: BPC-157, TB-500, KPV, MOTS-c, Semax and Epitalon. They are the six that FDA's Pharmacy Compounding Advisory Committee voted in July 2026 to recommend for the 503A bulks list. The policy is a draft statement of enforcement discretion. It does not add them to the bulks list or make them FDA-approved drugs.

What do FDA's 503A Category 1, 2 and 3 mean?

They sort bulk drug substances nominated for compounding that have no USP monograph and are not components of FDA-approved drugs. Category 1 is under evaluation with no significant safety risks identified. Category 2 has significant safety risks identified. Category 3 was nominated without adequate supporting information.

Is retatrutide FDA-approved?

No. As of November 10, 2026, Drugs@FDA lists no approved product containing retatrutide, and it is not in any 503A category. WADA's S0 class covers substances with no current approval by any health authority, which includes drugs still in clinical development.

Which peptides are on the WADA Prohibited List?

The 2026 List names BPC-157 (S0); CJC-1295, sermorelin, tesamorelin, ipamorelin, GHRP-2, GHRP-6 and hexarelin (S2.2.4); AOD-9604 (S2.2.3); TB-500, thymosin-β4, mechano growth factors and IGF-1 analogues (S2.3); kisspeptin and gonadorelin, in males (S2.2.1); follistatin and ACE-031 (S4.3); and MOTS-c (S4.4.1). GLP-1 receptor agonists such as semaglutide and tirzepatide are not on the List.

Sources

This page summarizes public regulatory documents for reference. It is not legal advice, and statuses change: check the linked source before relying on any entry. WADA's 2027 Prohibited List takes effect on January 1, 2027. For research and educational purposes only.

Last checked Nov 10, 2026